Abstract Book for the 27th Congress of the European Hematology Association Less HemaSphere. 6:1-4130, June 2022. Favorite PDF Permissions Open
S100: QUIZARTINIB PROLONGED SURVIVAL VS PLACEBO PLUS INTENSIVE INDUCTION AND CONSOLIDATION THERAPY FOLLOWED BY SINGLE-AGENT CONTINUATION IN PATIENTS AGED 18-75 YEARS WITH NEWLY DIAGNOSED FLT3-ITD+ AML Erba, H.; Montesinos, P.; Vrhovac, R.; More Erba, H.; Montesinos, P.; Vrhovac, R.; Patkowska, E.; Kim, H.-J.; Zak, P.; Wang, P.-N.; Mitov, T.; Hanyok, J.; Liu, L.; Benzohra, A.; Lesegretain, A.; Cortes, J.; Perl, A.; Sekeres, M.; Dombret, H.; Amadori, S.; Wang, J.; Levis, M.; Schlenk, R. Less HemaSphere. 6:1-2, June 2022. Favorite PDF Permissions Open
S101: GENETIC AND EPIGENETIC FACTORS DRIVING PRIMARY MEDIASTINAL B-CELL LYMPHOMA PATHOGENESIS AND OUTCOME Noerenberg, D.; Briest, F.; Hennch, C.; More Noerenberg, D.; Briest, F.; Hennch, C.; Yoshida, K.; Nimo, J.; Hablesreiter, R.; Takeuchi, Y.; Sasca, D.; Ueno, H.; Mansouri, L.; Inoue, Y.; Wiegand, L.; Staiger, A. M.; Casadei, B.; Ziepert, M.; Asmar, F.; Korkolopoulou, P.; Kirchner, M.; Mertins, P.; Weiner, J.; Toth, E.; Weber, T.; Warth, A.; Schneider, T.; Amini, R.-M.; Klapper, W.; Hummel, M.; Poeschel, V.; Kanellis, G.; Rosenwald, A.; Held, G.; Campo, E.; Stamatopoulos, K.; Anagnostopoulos, I.; Bullinger, L.; Goldschmidt, N.; Zinzani, P. L.; Bödor, C.; Rosenquist, R.; Vassilakopoulos, T. P.; Ott, G.; Ogawa, S.; Damm, F. Less HemaSphere. 6:2-3, June 2022. Favorite PDF Permissions Open
S102: COMPREHENSIVE GENOME CHARACTERIZATION REVEALS NEW SUBTYPES AND MECHANISMS OF ONCOGENE DEREGULATION IN CHILDHOOD T-ALL Pölönen, P.; Elsayed, A.; Montefiori, L.; More Pölönen, P.; Elsayed, A.; Montefiori, L.; Kimura, S.; Myers, J.; Hedges, D.; Xu, J.; Hui, Y.; Cheng, Z.; Fan, Y.; Chang, Y.; Shraim, R.; Devidas, M.; Winter, S.; Dunsmore, K.; Yang, J. J.; Vincent, T. L.; Tan, K.; Chen, C.; Newman, H.; Loh, M.; Raetz, E.; Hunger, S. P.; Rampersaud, E.; Chang, T.-C.; Wu, G.; Pounds, S.; Mullighan, C. G.; Teachey, D. T. Less HemaSphere. 6:3-4, June 2022. Favorite PDF Permissions Open
S103: EFFICACY AND SAFETY OF ARI0002H, AN ACADEMIC BCMA-DIRECTED CAR-T CELL THERAPY WITH FRACTIONATED INITIAL THERAPY AND BOOSTER DOSE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA Fernandez De Larrea, C.; González-Calle, V.; Oliver-Caldés, A.; More Fernandez De Larrea, C.; González-Calle, V.; Oliver-Caldés, A.; Cabañas, V.; Rodríguez-Otero, P.; Español-Rego, M.; Reguera, J. L.; López-Corral, L.; Martin-Antonio, B.; Paiva, B.; Inogés, S.; Rosiñol, L.; López-Díaz de Cerio, A.; Tovar, N.; López-Parra, M.; Rodríguez-Lobato, L. G.; Sánchez-Salinas, A.; Varea, S.; Ortiz-Maldonado, V.; Pérez Simón, J. A.; Prósper, F.; Juan, M.; Moraleda, J. M.; Mateos, M. V.; Pascal, M.; Urbano-Ispizua, A. Less HemaSphere. 6:4-5, June 2022. Favorite PDF Permissions Open
S104: RBPS DYSREGULATION CAUSE HYPER-NUCLEOLI AND RIBOSOME GAIN-OF-FUNCTION DRIVING BONE MARROW FAILURE Aguilar-Garrido, P.; Velasco, M.; Hernández Sánchez, M.; More Aguilar-Garrido, P.; Velasco, M.; Hernández Sánchez, M.; Navarro Aguadero, M. Á.; Malaney, P.; Aitken, M. JL; Zhang, X.; Young, K. H; Duan, R.; Hu, P.; Kornblau, S.; Fernández, A.; Ortiz, A.; Otero-Sobrino, Á.; de Andrés, P. J.; Megías, D.; Pérez, M.; Gómez, J.; Mata, G.; Martínez López, J.; Post, S.; Gallardo, M. Less HemaSphere. 6:5-6, June 2022. Favorite PDF Permissions Open
S105: IN VIVO PDX CRISPR/CAS9 SCREENS REVEAL MUTUAL THERAPEUTIC TARGETS TO OVERCOME HETEROGENEOUS ACQUIRED CHEMO-RESISTANCE Wirth, A.-K.; Wange, L.; Vosberg, S.; More Wirth, A.-K.; Wange, L.; Vosberg, S.; Jayavelu, A. K.; Enard, W; Herold, T; Jeremias, I Less HemaSphere. 6:6-7, June 2022. Favorite PDF Permissions Open
S106: UBTF-ATXN7L3 GENE FUSION DUE TO 17Q21.31 DELETION DEFINES NOVEL HIGH-RISK ALL SUBTYPE AMENABLE TO MRD-BASED TREATMENT INTENSIFICATION Bastian, L.; Hartmann, A.; Beder, T.; More Bastian, L.; Hartmann, A.; Beder, T.; Hänzelmann, S.; Kässens, J.; Bultmann, M.; Höppner, M. P.; Franzenburg, S.; Wittig, M.; Franke, A.; Nagel, I.; Spielmann, M.; Reimer, N.; Busch, H.; Schwartz, S.; Steffen, B.; Viardot, A.; Döhner, K.; Kondakci, M.; Wulf, G.; Wendelin, K.; Renzelmann, A.; Kiani, A.; Trautmann, H.; Neumann, M.; Gökbuget, N.; Brüggemann, M.; Baldus, C. Less HemaSphere. 6:7-8, June 2022. Favorite PDF Permissions Open
S107: SOD2 PROMOTES ACUTE LEUKEMIA ADAPTATION TO AMINO ACID STARVATION THROUGH THE N-DEGRON PATHWAY Ibrahim, N. K.; Schreek, S.; Cinar, B.; More Ibrahim, N. K.; Schreek, S.; Cinar, B.; Loxha, L.; Fehlhaber, B.; Bourquin, J.-P.; Bornhauser, B.; Eckert, C.; Cario, G.; Forster, M.; Stanulla, M.; Gutierrez, A.; Hinze, L. Less HemaSphere. 6:8-9, June 2022. Favorite PDF Permissions Open
S108: PEDIATRIC T- ALL RELAPSE: CONSTITUTIONAL CANCER PREDISPOSITION AND HYPERMUTATATOR PHENOTYPES Richter-Pechanska, P.; Kunz, J.; Rausch, T.; More Richter-Pechanska, P.; Kunz, J.; Rausch, T.; Erarslan-Uysal, B.; Bornhauser, B.; Frismantas, V.; Assenov, Y.; Zimmermann, M.; Happich, M.; von Knebel-Doeberitz, C.; von Neuhoff, N.; Koehler, R.; Stanulla, M.; Schrappe, M.; Cario, G.; Escherich, G.; Kischner-Schwabe, R.; Eckert, C.; Avigad, S.; Pfister, S.; Muckenthaler, M.; Bourquin, J.-P.; Korbel, J.; Kulozik, A. Less HemaSphere. 6:9-10, June 2022. Favorite PDF Permissions Open
S109: ONCOGENIC DEUBIQUITINATION CONTROLS TYROSINE KINASE SIGNALING AND THERAPY RESPONSE IN ACUTE LYMPHOBLASTIC LEUKEMIA Ntziachristos, P.; Jin, Q.; Gutierrez, B. Ntziachristos, P.; Jin, Q.; Gutierrez, B. Less HemaSphere. 6:10-11, June 2022. Favorite PDF Permissions Open
S110: A NOVEL AND SUCCESSFUL CD7 GENE KNOCKOUT CAR-T CELL THERAPY FOR RELAPSED OR REFRACTORY T-CELL HEMATOLOGIC MALIGNANCIES Yang, J.; Li, J.; Zhang, X.; More Yang, J.; Li, J.; Zhang, X.; Qiu, L.; Lu, P. Less HemaSphere. 6:11-12, June 2022. Favorite PDF Permissions Open
S111: REPEATED INFUSIONS OF ESCALATING DOSES OF EXPANDED AND ACTIVATED AUTOLOGOUS NATURAL KILLER CELLS IN MINIMAL RESIDUAL DISEASE-POSITIVE PH+ ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS. A GIMEMA PHASE 1 TRIAL Torelli, G. F.; Chiaretti, S.; Peragine, N.; More Torelli, G. F.; Chiaretti, S.; Peragine, N.; Barberi, W.; Santodonato, L.; D’Agostino, G.; Abruzzese, E.; Del Principe, M. I.; Mancino, A.; Matarazzo, M.; Bafti, M. S.; Mancini, M; Messina, M.; Castiello, L.; Guarini, A.; Foà, R. Less HemaSphere. 6:12-13, June 2022. Favorite PDF Permissions Open
S112: TISAGENLECLEUCEL IN PEDIATRIC AND YOUNG ADULT PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL): FINAL ANALYSES FROM THE ELIANA STUDY Rives, S.; Maude, S. L.; Hiramatsu, H.; More Rives, S.; Maude, S. L.; Hiramatsu, H.; Baruchel, A.; Bader, P.; Bittencourt, H.; Buechner, J.; Laetsch, T.; De Moerloose, B.; Qayed, M.; Stefanski, H. E.; Davis, K. L.; Martin, P. L.; Nemecek, E.; Peters, C.; Yanik, G.; Balduzzi, A.; Boissel, N.; Khaw, S. L.; Krueger, J.; Levine, J.; Davies, S.; Myers, G. D.; Yeo, A.; O’Donovan, D.; Ramos, R.; Pulsipher, M.; Grupp, S. Less HemaSphere. 6:13-14, June 2022. Favorite PDF Permissions Open
S113: NATIONAL PEGASPARGASE-MODIFIED RISK-ORIENTED PROGRAM FOR PHILADELPHIA-NEGATIVE ADULT ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOBLASTIC LYMPHOMA (PH− ALL/LL). GIMEMA LAL 1913 FINAL RESULTS. Bassan, R.; Chiaretti, S.; Della Starza, I.; More Bassan, R.; Chiaretti, S.; Della Starza, I.; Spinelli, O.; Santoro, A.; Elia, L.; De Propris, M. S.; Scattolin, A. M.; Paoloni, F.; Messina, M.; Audisio, E.; Marbello, L.; Borlenghi, E.; Zappasodi, P.; Vetro, C.; Martinelli, G.; Mattei, D.; Fracchiolla, N.; Bocchia, M.; De Fabritiis, P.; Bonifacio, M.; Candoni, A.; Cassibba, V.; Di Bartolomeo, P.; Latte, G.; Trappolini, S.; Guarini, A.; Vitale, A.; Fazi, P.; Vignetti, M.; Rambaldi, A.; Foà, R. Less HemaSphere. 6:14-15, June 2022. Favorite PDF Permissions Open
S114: PONATINIB AND BLINATUMOMAB FOR PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA: UPDATED RESULTS FROM A PHASE II STUDY Short, N.; Kantarjian, H.; Konopleva, M.; More Short, N.; Kantarjian, H.; Konopleva, M.; Jain, N.; Ravandi, F.; Huang, X.; Macaron, W.; Wierda, W.; Borthakur, G.; Kadia, T.; Sasaki, K.; Issa, G.; Montalban-Bravo, G.; Alvarado, Y.; Garcia-Manero, G.; Dinardo, C.; Thankachan, J.; Delumpa, R.; Mayor, E.; Deen, W.; Milton, A.; Rivera, J.; Waller, L.; Loiselle, C.; Garris, R.; Jabbour, E. Less HemaSphere. 6:15-16, June 2022. Favorite PDF Permissions Open
S115: MUTANT NPM1 BINDS CHROMATIN AND COOPERATES WITH MLL1 TO REGULATE ONCOGENIC TRANSCRIPTION Uckelmann, H.; Armstrong, S.; Haarer, E.; More Uckelmann, H.; Armstrong, S.; Haarer, E.; Wong, E.; Hatton, C.; Perner, F.; Marinaccio, C.; Chen, C.-W. Less HemaSphere. 6:16-17, June 2022. Favorite PDF Permissions Open
S116: CELLULAR AND MOLECULAR MECHANISMS OF EVI1-EXPRESSING MLL-REARRANGED ACUTE MYELOID LEUKEMIA Châtel-Soulet, Hugues-Etienne; Juge, Sabine; Pereira, Ana Luisa; More Châtel-Soulet, Hugues-Etienne; Juge, Sabine; Pereira, Ana Luisa; Otzen Bagger, Frederik; Tzankov, Alexandar; Kurokawa, Mineo; El Taher, Athimed; Seguin, Jonathan; Nombela Arrieta, César; Schwaller, Juerg Less HemaSphere. 6:17-18, June 2022. Favorite PDF Permissions Open
S117: EVI1 DRIVES LEUKEMOGENESIS THROUGH ABERRANT ERG ACTIVATION Schmoellerl, J.; Barbosa, I.; Minnich, M.; More Schmoellerl, J.; Barbosa, I.; Minnich, M.; Andersch, F.; Smeenk, L.; Havermans, M.; Eder, T.; Neumann, T.; Jude, J.; Fellner, M.; Ebert, A.; Steininger, M.; Delwel, R.; Grebien, F.; Zuber, J. Less HemaSphere. 6:18-19, June 2022. Favorite PDF Permissions Open
S118: IDENTIFICATION OF DIRECT TRANSCRIPTIONAL TARGET GENES OF NUP98-KDM5A REVEALS REGULATORY NETWORKS IN ACUTE MYELOID LEUKEMIA Troester, S.; Schmoellerl, J.; Eder, T.; More Troester, S.; Schmoellerl, J.; Eder, T.; Manhart, G.; Winter, G.; Zuber, J.; Grebien, F. Less HemaSphere. 6:19-20, June 2022. Favorite PDF Permissions Open
S119: CEBPA AND TET2 MUTATIONS COOPERATE TO INDUCE AGGRESSIVE AML VIA GATA-2 DOWNREGULATION Heyes, E.; Wilhelmson, A. S.; Wenzel, A.; More Heyes, E.; Wilhelmson, A. S.; Wenzel, A.; Schuster, M. B.; Ali, M.; D’Altri, T.; Eder, T.; Manhart, G.; Rzepa, E.; Schmidt, L.; Meggendorfer, M.; Haferlach, T.; Volpe, G.; Nerlov, C.; Frampton, J.; Jae Won, K.; Grebien, F.; Porse, B. Less HemaSphere. 6:20-21, June 2022. Favorite PDF Permissions Open
S120: ACUTE MYELOID LEUKEMIA REPRESENTS A FERROPTOSIS-SENSITIVE CANCER ENTITY RAISING THE POSSIBILITY FOR NOVEL TARGETING STRATEGIES Narr, A.; Alborzinia, H.; Donato, E.; More Narr, A.; Alborzinia, H.; Donato, E.; Vogel, F.; Boch, T.; Leppä, A.-M.; Waclawiczek, A.; Renders, S.; Schulze, A.; Trumpp, A. Less HemaSphere. 6:21-22, June 2022. Favorite PDF Permissions Open
S121: CD123-CD33 COMPOUND CAR-T CELLS WITH NOVEL ANTIGEN BINDING DOMAINS PROVIDE A NEW HOPE FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA Wang, Z.; LU, Y.; Qiu, S.; More Wang, Z.; LU, Y.; Qiu, S.; Wang, M.; Xiong, D.; Wang, J. Less HemaSphere. 6:22-23, June 2022. Favorite PDF Permissions Open
S122: ROCK INHIBITORS TARGET SRSF2 LEUKEMIA BY DISRUPTING CELL MITOSIS AND NUCLEAR MORPHOLOGY Su, M.; Fleisher, T.; Grosheva, I.; More Su, M.; Fleisher, T.; Grosheva, I.; Horev, M.; Olszewska, M.; Haim, B.; Plotnikov, A.; Carvalho, S.; Moskovitz, Y.; Minden, M; Chapal-Ilani, N.; Papapetrou, E.; Dezorella, N.; Cheng, T.; Kaushansky, N.; Geiger, B; Shlush, L. Less HemaSphere. 6:23-24, June 2022. Favorite PDF Permissions Open
S123: DECODING TRANSCRIPTOMIC AND EPIGENETIC CONSEQUENCES OF STRUCTURAL VARIANTS IN CK-AML AT SINGLE-CELL RESOLUTION Leppä, A.-M.; Grimes, K.; Jeong, H.; More Leppä, A.-M.; Grimes, K.; Jeong, H.; Boch, T.; Karpova, D; Jauch, A.; Grünschläger, F.; Dolnik, A.; Bullinger, L.; Krämer, A.; Sanders, A. D.; Korbel, J. O.; Trumpp, A. Less HemaSphere. 6:24-25, June 2022. Favorite PDF Permissions Open
S124: BONE MORPHOGENETIC PROTEIN 2 TRIGGERS OFF AN IMMUNOSUPPRESSIVE EFFECT OF ΓΔ T CELLS IN ACUTE MYELOID LEUKEMIA Liang, S.; Dong, T.; Yue, K.; More Liang, S.; Dong, T.; Yue, K.; Gao, H.; Wu, N.; Liu, R.; Liu, J.; Huang, X.-J. Less HemaSphere. 6:25-26, June 2022. Favorite PDF Permissions Open
S125: 10-DAY DECITABINE VS. CONVENTIONAL CHEMOTHERAPY (“3 + 7”) FOLLOWED BY ALLOGRAFTING (HSCT) IN AML PATIENTS ≥60 YEARS: A RANDOMIZED PHASE III STUDY OF THE EORTC LEUKEMIA GROUP, GIMEMA, CELG, AND GMDS-SG Lübbert, M.; Wijermans, P.; Kicinski, M.; More Lübbert, M.; Wijermans, P.; Kicinski, M.; Chantepie, S.; van der Velden, W.; Noppeney, R.; Griskevicius, L.; Neubauer, A.; Crysandt, M.; Vrhovac, R.; Luppi, M.; Fuhrmann, S.; Audisio, E.; Candoni, A.; Legrand, O.; Foà, R.; Gaidano, G.; van Lammeren-Venema, D.; Posthuma, E. F.; Hoogendoorn, M.; Giraut, A.; Stevens-Kroef, M.; Jansen, J. H.; Ammatuna, E.; Vilque, J.-P.; Wäsch, R.; Becker, H.; Blijlevens, N.; Dührsen, U.; Baron, F.; Suciu, S.; Amadori, S.; Venditti, A.; Huls, G. Less HemaSphere. 6:26-27, June 2022. Favorite PDF Permissions Open
S126: GEMTUZUMAB-BASED INDUCTION CHEMOTHERAPY COMBINED WITH MIDOSTAURIN FOR FLT3 MUTATED AML. RESULTS FROM THE NCRI AML19 “MIDOTARG” PILOT TRIAL Russell, N.; Wilhelm-Benartzi, C.; Othman, J.; More Russell, N.; Wilhelm-Benartzi, C.; Othman, J.; Dillon, R.; Potter, N.; Jovanovic, J.; Gilkes, A.; Batten, L. M.; Canham, J.; Hinson, E. L.; Kottaridis, P.; Cavenagh, J.; Arnold, C.; Dennis, M.; Knapper, S. Less HemaSphere. 6:27-28, June 2022. Favorite PDF Permissions Open
S127: QUIZARTINIB WITH DECITABINE AND VENETOCLAX (TRIPLET) IS ACTIVE IN PATIENTS WITH FLT3-ITD MUTATED ACUTE MYELOID LEUKEMIA - A PHASE I/II STUDY Yilmaz, M.; Muftuoglu, M.; Kantarjian, H.; More Yilmaz, M.; Muftuoglu, M.; Kantarjian, H.; DiNardo, C.; Kadia, T.; Borthakur, G.; Pemmaraju, N.; Short, N.; Alvarado, Y.; Maiti, A.; Masarova, L.; Montalban Bravo, G.; Loghavi, S.; Patel, K.; Kornblau, S.; Jabbour, E.; Garcia-Manero, G.; Andreeff, M.; Daver, N. Less HemaSphere. 6:28-29, June 2022. Favorite PDF Permissions Open
S128: A RANDOMISED COMPARISON OF CPX-351 AND FLAG-IDA IN HIGH RISK ACUTE MYELOID LEUKAEMIA. RESULTS FROM THE NCRI AML19 TRIAL Russell, N.; Wilhelm-Benartzi, C.; Knapper, S.; More Russell, N.; Wilhelm-Benartzi, C.; Knapper, S.; Batten, L.; Canham, J; Hinson, E.; Malthe Overgaard, U.; Othman, J.; Dillon, R.; Mehta, P.; Kottaridis, P.; Cavenagh, J.; Hemmaway, C.; Arnold, C.; Dennis, M. Less HemaSphere. 6:29-30, June 2022. Favorite PDF Permissions Open
S129: TAKEAIM LEUKEMIA- A PHASE 1/2A STUDY OF THE IRAK4 INHIBITOR EMAVUSERTIB (CA-4948) AS MONOTHERAPY OR IN COMBINATION WITH AZACITIDINE OR VENETOCLAX IN RELAPSED/REFRACTORY AML OR MDS Garcia-Manero, G.; Winer, E. S.; DeAngelo, D. J.; More Garcia-Manero, G.; Winer, E. S.; DeAngelo, D. J.; Tarantolo, S.; Sallman, D. A.; Dugan, J.; Groepper, S.; Giagounidis, A.; Götze, K.; Metzeler, K. H.; Li, C.-C.; Zhou, L.; Martinez, E.; Lane, M.; von Roemeling, R.; Bohme, M.; Kubasch, A. S.; Verma, A.; Platzbecker, U. Less HemaSphere. 6:30-31, June 2022. Favorite PDF Permissions Open
S130: NPM1 MUTATED AML: IMPACT OF CO-MUTATIONAL PATTERNS - RESULTS OF THE EUROPEAN HARMONY ALLIANCE Hernández-Sánchez, A.; Villaverde-Ramiro, Á.; Martínez Elicegui, J.; More Hernández-Sánchez, A.; Villaverde-Ramiro, Á.; Martínez Elicegui, J.; González, T.; Benner, A.; Sträng, E.; Castellani, G.; Heckman, C. A.; Versluis, J.; Abáigar, M.; Sobas, M.; Azibeiro, R.; Tur, L.; Valk, P. J.; Metzeler, K. H.; Ayala, R.; Dall’Olio, D.; Tettero, J.; Martínez-López, J.; Dombret, H.; Pratcorona, M.; Damm, F.; Mills, K. I.; Mayer, J.; Thiede, C.; Voso, M. T.; Sanz, G. F.; Calado, F.; Döhner, K.; Gaidzik, V. I.; Heuser, M.; Haferlach, T.; Turki, A. T.; Reinhardt, D.; Villoria Medina, R.; van Speybroeck, M.; Schulze-Rath, R.; Barbus, M.; Butler, J. E.; Hernández Rivas, J. M.; Huntly, B. J.; Ossenkoppele, G. J.; Döhner, H.; Bullinger, L. Less HemaSphere. 6:31-32, June 2022. Favorite PDF Permissions Open
S131: CLINICAL IMPLICATIONS OF SECONDARY-AML TYPE MUTATIONS IN PATIENTS WITH DE NOVO ACUTE MYELOID LEUKEMIA Sun, K.; Tsai, C.-H.; Lo, M.-Y.; More Sun, K.; Tsai, C.-H.; Lo, M.-Y.; Tseng, M.-H.; Kuo, Y.-Y.; Liu, M.-C.; Lin, C.-C.; Cheng, C.-L.; Wu, S.-J.; Chen, C.-Y.; Ko, B.-S.; Yao, M.; Chou, W.-C.; Hou, H.-A.; Tien, H.-F. Less HemaSphere. 6:32-33, June 2022. Favorite PDF Permissions Open
S132: TOLERABILITY AND EFFICACY OF THE FIRST-IN-CLASS ANTI-CD47 ANTIBODY MAGROLIMAB COMBINED WITH AZACITIDINE IN FRONTLINE PATIENTS WITH TP53-MUTATED ACUTE MYELOID LEUKEMIA: PHASE 1B RESULTS Daver, N. G.; Vyas, P.; Kambhampati, S.; More Daver, N. G.; Vyas, P.; Kambhampati, S.; Al Malki, M. M.; Larson, R.; Asch, A.; Mannis, G.; Chai-Ho, W.; Tanaka, T.; Bradley, T.; Jeyakumar, D.; Wang, E.; Xing, G.; Chao, M.; Ramsingh, G.; Renard, C.; Lal, I.; Zeidner, J.; Sallman, D. Less HemaSphere. 6:33-34, June 2022. Favorite PDF Permissions Open
S133: OFF-THE-SHELF CD33 CAR-NK CELL THERAPY FOR RELAPSE/REFRACTORY AML: FIRST-IN-HUMAN, PHASE I TRIAL Huang, R.; Wen, Q.; Wang, X.; More Huang, R.; Wen, Q.; Wang, X.; Yan, H.; Ma, Y.; Wang, M.; Han, X.; Gao, L.; Gao, L.; Zhang, C.; Zhang, X. Less HemaSphere. 6:34-35, June 2022. Favorite PDF Permissions Open
S134: INTRA-PATIENT FUNCTIONAL HETEROGENEITY OF AML DETERMINES FIRST-LINE TREATMENT RESPONSE Severin, Y.; Festl, Y.; Roiss, M.; More Severin, Y.; Festl, Y.; Roiss, M.; Benoit, T.; Heinemann, T.; Wegmann, R.; Kienzler, A.-K.; Bissig, M.; Scharl, M.; Manz, M.; Müller, A. M.; Snijder, B. Less HemaSphere. 6:35-36, June 2022. Favorite PDF Permissions Open
S135: CRISPR/CAS9 EDITING REVEALS DEPENDENCE OF HUMAN RICHTER SYNDROME AND MURINE CLL CELLS ON SIGNALS FROM B CELL RECEPTOR, CXCR4 RECEPTOR AND MACROPHAGES BUT NOT FROM TOLL-LIKE RECEPTORS IN VIVO Martines, C.; Chakraborty, S.; Guastafierro, V.; More Martines, C.; Chakraborty, S.; Guastafierro, V.; Vujovikj, M.; Vaisitti, T.; Deaglio, S.; Laurenti, L.; Dimovski, A.; Efremov, D. Less HemaSphere. 6:36-37, June 2022. Favorite PDF Permissions Open
S136: CONSTITUTIVE VLA-4 ACTIVATION IN CHRONIC LYMPHOCYTIC LEUKEMIA. THE OTHER SIDE OF BCR AUTONOMOUS SIGNALING. Tissino, E.; Bomben, R.; Maity, P. C.; More Tissino, E.; Bomben, R.; Maity, P. C.; Pozzo, F.; Forestieri, G.; Nicolò, A.; Härzschel, A.; Bittolo, T.; Rossi, F. M.; Datta, M.; Zaja, F.; Capasso, G.; D’Arena, G.; Chiarenza, A.; Di Raimondo, F.; Jumaa, H.; Rossi, D.; Del Poeta, G.; Hartmann, T. N.; Zucchetto, A.; Gattei, V. Less HemaSphere. 6:37-38, June 2022. Favorite PDF Permissions Open
S137: SMALL EXTRACELLULAR VESICLES IN THE LEUKEMIA MICROENVIRONMENT SUSTAIN CLL PROGRESSION BY HAMPERING T CELL-MEDIATED ANTI-TUMOR IMMUNITY Gargiulo, E.; Viry, E.; Morande, P. E.; More Gargiulo, E.; Viry, E.; Morande, P. E.; Largeot, A.; Gonder, S.; Xian, F.; Ioannou, N.; Benzarti, M.; Kleine Borgmann, F.; Mittelbronn, M.; Dittmar, G.; Nazarov, P. V.; Meiser, J.; Stamatopoulos, B.; Ramsay, A. G.; Moussay, E.; Paggetti, J. Less HemaSphere. 6:38-39, June 2022. Favorite PDF Permissions Open
S138: MICROENVIRONMENT-REGULATED TRANSCRIPTIONS FACTORS AHR AND HIF-1Α EXPRESSION IN TREGS PROMOTE CLL PROGRESSION BY IMPAIRING CD8+ T-CELL MEDIATED ANTI-TUMOR IMMUNITY Pagano, G.; Wierz, M.; Fernandez Botana, I.; More Pagano, G.; Wierz, M.; Fernandez Botana, I.; Gonder, S.; Gargiulo, E.; Moussay, E.; Paggetti, J. Less HemaSphere. 6:39-40, June 2022. Favorite PDF Permissions Open
S139: BCOR DELETION SUSTAINS NOTCH1 SIGNALLING ACTIVATION TO ACCELERATE CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PROGRESSION TOWARD RICHTER TRANSFORMATION IN MICE Rompietti, C.; Sorcini, D.; De Falco, F.; More Rompietti, C.; Sorcini, D.; De Falco, F.; Dorillo, E.; Adamo, F. M.; Silva Barcelos, E. C.; Stella, A.; Scialdone, A.; Esposito, A.; Arcaleni, R.; Bigerna, B.; Martino, G.; Moretti, L.; Mameli, M. G.; Geraci, C.; Sandoletti, L.; Cipiciani, A.; Rosati, E.; Falini, B.; Sportoletti, P. Less HemaSphere. 6:40-41, June 2022. Favorite PDF Permissions Open
S140: SINGLE-CELL MULTIOMICS ANALYSES REVEAL COMPLEX INTRA-PATIENT HETEROGENEITY IN RELAPSED CLL FOLLOWING VENETOCLAX THERAPY Thijssen, R.; Tian, L.; Flensburg, C.; More Thijssen, R.; Tian, L.; Flensburg, C.; Anderson, M. A.; Jarratt, A.; Peng, H.; Majewski, I.; Tam, C.; Seymour, J.; Blombery, P.; Ritchie, M.; Huang, D.; Roberts, A. Less HemaSphere. 6:41-42, June 2022. Favorite PDF Permissions Open
S141: ELICITING ANTI-TUMOR T CELL ACTIVITY IN CHRONIC LYMPHOCYTIC LEUKEMIA WITH BISPECIFIC ANTIBODY-BASED COMBINATION THERAPY Papazoglou, D.; Ysebaert, L.; Ioannou, N.; More Papazoglou, D.; Ysebaert, L.; Ioannou, N.; Apollonio, B.; Patten, P.; Herter, S.; Bacac, M.; Deutsch, A.; Klein, C.; Vardi, A.; Quillet-Mary, A.; Ramsay, A. Less HemaSphere. 6:42-43, June 2022. Favorite PDF Permissions Open
S142: DECIPHERING THE COMPLEXITY OF T CELLS IN BLOOD AND LYMPH NODES OF PATIENTS WITH CLL BY INTEGRATIVE SINGLE-CELL RNA-SEQ AND MASS CYTOMETRY ANALYSES Llaó Cid, L.; Wong, J.; Wierz, M.; More Llaó Cid, L.; Wong, J.; Wierz, M.; Paul, Y.; Gonder, S.; Fernandez Botana, I.; Roider, T.; Dietrich, S.; Colomer, D.; Lichter, P.; Zapatka, M.; Moussay, E.; Paggetti, J.; Seiffert, M. Less HemaSphere. 6:43-44, June 2022. Favorite PDF Permissions Open
S143: TRANSCRIPTOMIC CHARACTERIZATION OF MRD RESPONSE AND NON-RESPONSE IN PATIENTS TREATED WITH FIXED-DURATION VENETOCLAX-OBINUTUZUMAB Al-Sawaf, O.; Jin, H. Y.; Zhang, C.; More Al-Sawaf, O.; Jin, H. Y.; Zhang, C.; Choi, Y.; Balasubramanian, S.; Robrecht, S.; Kotak, A.; Chang, N.; Fink, A.-M.; Tausch, E.; Schneider, C.; Ritgen, M.; Kreuzer, K.-A.; Chyla, B.; Paulson, J.; Eichhorst, B.; Stilgenbauer, S.; Jiang, Y.; Hallek, M.; Fischer, K. Less HemaSphere. 6:44-45, June 2022. Favorite PDF Permissions Open
S144: IMMUNE RESTORATION AND SYNERGISTIC ACTIVITY WITH FIRST-LINE (1L) IBRUTINIB (IBR) PLUS VENETOCLAX (VEN): TRANSLATIONAL ANALYSES OF CAPTIVATE PATIENTS WITH CLL Solman, I.; Singh Mali, R.; Scarfo, L.; More Solman, I.; Singh Mali, R.; Scarfo, L.; Choi, M.; Moreno, C.; Grigg, A.; Dean, J. P.; Szafer-Glusman, E. Less HemaSphere. 6:45-46, June 2022. Favorite PDF Permissions Open
S145: THE COMBINATION OF IBRUTINIB PLUS VENETOCLAX RESULTS IN A HIGH RATE OF MRD NEGATIVITY IN PREVIOUSLY UNTREATED CLL: THE RESULTS OF THE PLANNED INTERIM ANALYSIS OF THE PHASE III NCRI FLAIR TRIAL Hillmen, P.; Pitchford, A.; Bloor, A.; More Hillmen, P.; Pitchford, A.; Bloor, A.; Pettitt, A.; Patten, P.; Forconi, F.; Schuh, A.; Fox, C.; Elmusharaf, N.; Gatto, S.; Kennedy, B.; Gribben, J.; Pemberton, N.; Sheehy, O.; Preston, G.; Howard, D.; Hockaday, A.; Cairns, D.; Jackson, S.; Greatorex, N.; Webster, N.; Dalal, S.; Shingles, J.; Cwynarski, K.; Paneesha, S.; Allsup, D.; Rawstron, A.; Munir, T. Less HemaSphere. 6:46-47, June 2022. Favorite PDF Permissions Open
S146: VENETOCLAX IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA WITH 17P DELETION: 6-YEAR FOLLOW-UP AND GENOMIC ANALYSES IN A PIVOTAL PHASE 2 TRIAL Stilgenbauer, S.; Tausch, E.; Roberts, A. W.; More Stilgenbauer, S.; Tausch, E.; Roberts, A. W.; Davids, M. S.; Eichhorst, B.; Hallek, M.; Hillmen, P.; Schneider, C.; Böttcher, S.; Popovic, R.; Ghanim, M. T.; Moran, M.; Sinai, W. J.; Wang, X.; Mukherjee, N.; Chyla, B.; Wierda, W. G.; Seymour, J. F. Less HemaSphere. 6:47-48, June 2022. Favorite PDF Permissions Open
S147: PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REVERSIBLE) BTK INHIBITOR IN PREVIOUSLY TREATED CLL/SLL: UPDATED RESULTS FROM THE PHASE 1/2 BRUIN STUDY Mato, A. R.; Pagel, J. M.; Coombs, C. C.; More Mato, A. R.; Pagel, J. M.; Coombs, C. C.; Shah, N. N.; Lamanna, N.; Munir, T.; Lech-Maranda, E.; Eyre, T. A.; Woyach, J. A.; Wierda, W. G.; Cheah, C. Y.; Cohen, J. B.; Roeker, L. E.; Patel, M. R.; Fakhri, B.; Barve, M. A.; Tam, C.; Lewis, D.; Gerson, J. N.; Alencar, A. J.; Ujjani, C.; Flinn, I.; Sundaram, S.; Ma, S.; Jagadeesh, D.; Rhodes, J.; Taylor, J.; Abdel-Wahab, O.; Ghia, P.; Schuster, S. J.; Wang, D.; Nair, B.; Zhu, E.; Tsai, D. E.; Davids, M. S.; Brown, J. R.; Jurczak, W. Less HemaSphere. 6:48-49, June 2022. Favorite PDF Permissions Open
S148: VENETOCLAX-OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 5-YEAR RESULTS OF THE RANDOMIZED CLL14 STUDY Al-Sawaf, O.; Zhang, C.; Robrecht, S.; More Al-Sawaf, O.; Zhang, C.; Robrecht, S.; Kotak, A.; Chang, N.; Fink, A.-M.; Tausch, E.; Schneider, C.; Ritgen, M.; Kreuzer, K.-A.; Chyla, B.; Eichhorst, B.; Jiang, Y.; Stilgenbauer, S.; Hallek, M.; Fischer, K. Less HemaSphere. 6:49-50, June 2022. Favorite PDF Permissions Open
S149: LONG TERM OUTCOMES OF IFCG REGIMEN FOR FIRSTLINE TREATMENT OF PATIENTS WITH CLL WITH MUTATED IGHV AND WITHOUT DEL(17P)/TP53 MUTATION Jain, N.; Thompson, P.; Burger, J.; More Jain, N.; Thompson, P.; Burger, J.; Ferrajoli, A.; Takahashi, K.; Estrov, Z.; Borthakur, G.; Bose, P.; Kadia, T.; Pemmaraju, N.; Sasaki, K.; Konopleva, M.; Jabbour, E.; Garg, N.; Wang, X.; Kanagal-Shamanna, R.; Patel, K.; Wang, W.; Wang, S.; Jorgensen, J.; Lopez, W.; Ayala, A.; Plunkett, W.; Gandhi, V.; Kantarjian, H.; O’Brien, S.; Keating, M.; Wierda, W. Less HemaSphere. 6:50-51, June 2022. Favorite PDF Permissions Open
S150: BIOLOGY AND FUNCTION OF CIRCULAR PCMDT1 IN CHRONIC MYELOID LEUKEMIA IN BLAST CRISIS (CML-BC) Prathap Urs, A.; Papaioannou, D.; Buisson, R.; More Prathap Urs, A.; Papaioannou, D.; Buisson, R.; Khanal, S.; Karunasiri, M.; Kauppinen, S.; Dorrance, A.; Garzon, R. Less HemaSphere. 6:51-52, June 2022. Favorite PDF Permissions Open
S151: HIGH-THROUGHPUT EVALUATION OF THE POTENTIAL OF CANCER DRUGS TO ENHANCE NATURAL KILLER CELL IMMUNOTHERAPY IN CHRONIC MYELOID LEUKEMIA. Nygren, P.; Bouhlal, J.; Laajala, E.; More Nygren, P.; Bouhlal, J.; Laajala, E.; Ianevski, A.; Klievink, J.; Lähteenmäki, H.; Saeed, K.; Lee, D.; Aittokallio, T.; Dufva, O.; Mustjoki, S. Less HemaSphere. 6:52-53, June 2022. Favorite PDF Permissions Open
S152: SETD2/H3K36ME3 DEFICIENCY SUSTAINS GENOMIC INSTABILITY AND ENHANCES CLONOGENIC POTENTIAL OF CHRONIC MYELOID LEUKEMIA (CML) PROGENITORS Mancini, M.; De Santis, S.; Monaldi, C.; More Mancini, M.; De Santis, S.; Monaldi, C.; Bruno, S.; Castagnetti, F.; Gugliotta, G.; Iurlo, A.; Cerrano, M.; Galimberti, S.; Balducci, S.; Stagno, F.; Rosti, G.; Cavo, M.; Soverini, S. Less HemaSphere. 6:53-54, June 2022. Favorite PDF Permissions Open
S153: DECRYPTING THE ROLE OF HSP90Α AND Β ISOFORMS TO OVERCOME RESISTANCE IN BCR-ABL1 LEUKEMIA Vogt, M.; Dienstbier, N.; Schliehe-Diecks, J.; More Vogt, M.; Dienstbier, N.; Schliehe-Diecks, J.; Scharov, K.; Tu, J.-W.; Gebing, P.; Hogenkamp, J.; Picard, D.; Lenz, T.; Stühler, K.; Wagener, R.; Pandyra, A.; Hauer, J.; Fischer, U.; Borkhardt, A.; Bhatia, S. Less HemaSphere. 6:54-55, June 2022. Favorite PDF Permissions Open
S154: IMATINIB-RESISTANT CLONES ISOLATED FROM A MODEL OF BLAST CRISIS OF CHRONIC MYELOID LEUKAEMIA DIFFER IN MUTATIONS IN BCR::ABL1 AND OTHER CANCER RELATED GENES AND IN THEIR SENSITIVITY TO BH3-MIMETICS Laznicka, A.; Curik, N.; Polivkova, V.; More Laznicka, A.; Curik, N.; Polivkova, V.; Koblihova, J.; Burda, P.; Dolnikova, A.; Pokorna, E.; Salek, C.; Klamova, H.; Srbova, D.; Klener, P.; Machova Polakova, K. Less HemaSphere. 6:55-56, June 2022. Favorite PDF Permissions Open
S155: EFFICACY AND SAFETY RESULTS FROM ASCEMBL, A PHASE 3 STUDY OF ASCIMINIB VS BOSUTINIB IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE AFTER ≥2 PRIOR TYROSINE KINASE INHIBITORS: WK 96 UPDATE Rea, D.; Hochhaus, A.; Mauro, M. J.; More Rea, D.; Hochhaus, A.; Mauro, M. J.; Minami, Y.; Lomaia, E.; Voloshin, S.; Turkina, A.; Kim, D.-W.; Apperley, J. F.; Cortes, J. E.; Abdo, A.; Fogliatto, L. M.; Kim, D. D. H; le Coutre, P.; Saussele, S.; Annunziata, M.; Hughes, T. P.; Chaudhri, N.; Chee, L.; García-Gutiérrez, V.; Sasaki, K.; Kapoor, S.; Allepuz, A.; Quenet, S.; Bédoucha, V.; Boquimpani, C. Less HemaSphere. 6:56-57, June 2022. Favorite PDF Permissions Open
S156: INTERNATIONAL, PROSPECTIVE STUDY COMPARING NILOTINIB VERSUS IMATINIB WITH EARLY SWITCH TO NILOTINIB TO OBTAIN SUSTAINED TREATMENT-FREE REMISSION IN PATIENTS WITH WITH CHRONIC MYELOID LEUKEMIA Pane, F.; Castagnetti, F.; Luciano, L.; More Pane, F.; Castagnetti, F.; Luciano, L.; Russo Rossi, A.; Abruzzese, E.; Bassan, R.; Binotto, G.; Caocci, G.; Cimino, G.; Fazi, P.; Gozzini, A.; Lunghi, M.; Marasca, R.; Martino, B.; Bonifacio, M.; Cavazzini, F.; Paoloni, F.; Saglio, G.; Sica, S.; Tafuri, A.; Vallisa, D.; Vignetti, M.; Westerweel, P.; Rosti, G.; Breccia, M. Less HemaSphere. 6:57-58, June 2022. Favorite PDF Permissions Open
S157: BCR::ABL1 DIGITAL PCR IDENTIFIES CHRONIC PHASE CML PATIENTS SUITABLE FOR AN EARLY TKI DISCONTINUATION ATTEMPT: A PATIENT-LEVEL META-ANALYSIS Kockerols, C.; Dulucq, S.; Bernardi, S.; More Kockerols, C.; Dulucq, S.; Bernardi, S.; Farina, M.; Civettini, I.; Colafigli, G.; Mori, S.; Valk, P.; Mahon, F.-X.; Gambacorti-Passerini, C.; Nicolini, F.-E.; Breccia, M.; Russo, D.; Westerweel, P. E. Less HemaSphere. 6:58-59, June 2022. Favorite PDF Permissions Open
S158: FINAL RESULT OF TKI DISCONTINUATION TRIAL WITH DASATINIB FOR SECOND ATTEMPT OF TREATMENT FREE REMISSION AFTER FAILING FIRST ATTEMPT WITH IMATINIB: TREATMENT-FREE REMISSION ACCOMPLISHED BY DASATINIB Kim, D.; Atenafu, E.; Forrest, D.; More Kim, D.; Atenafu, E.; Forrest, D.; Bence-Bruckler, I.; Savoie, L.; Keating, M.-M.; Busque, L.; Delage, R.; Xenocostas, A.; Liew, E.; Laneuville, P.; Paulson, K.; Stockley, T.; Lipton, J.; Leber, B. Less HemaSphere. 6:59-60, June 2022. Favorite PDF Permissions Open
S159: QUÉBEC CML RESEARCH GROUP ANALYSIS OF TREATMENT PATTERNS IN CHRONIC MYELOGENOUS LEUKEMIA: SWITCHING IS DRIVEN BY INTOLERANCE AND SIMILAR ACROSS TYROSINE KINASE INHIBITORS AND LINES OF TREATMENT Busque, L.; Harnois, M.; Szuber, N.; More Busque, L.; Harnois, M.; Szuber, N.; Delage, R.; Mollica, L.; Olney, H.; Laneuville, P.; Sirhan, S.; Cournoyer, G.; Chamakhi, I.; Lalancette, M.; Talbot, D.; Éthier, V.; Desjardins, P.; Assouline, S. Less HemaSphere. 6:60-61, June 2022. Favorite PDF Permissions Open
S160: MOLECULAR DETERMINANTS OF DISEASE PROGRESSION AFTER HYPOMETHYLATING AGENT THERAPY IN RAS PATHWAY MUTANT CHRONIC MYELOMONOCYTIC LEUKEMIA AT THE SINGLE-CELL LEVEL Montalban-Bravo, G.; Ma, F.; Ganan-Gomez, I.; More Montalban-Bravo, G.; Ma, F.; Ganan-Gomez, I.; Kanagal-Shamana, R.; Adema, V.; Thongon, N.; Yang, H.; Soltysiak, K. A.; Bueso-Ramos, C.; Kantarjian, H.; Garcia-Manero, G.; Colla, S. Less HemaSphere. 6:61-62, June 2022. Favorite PDF Permissions Open
S161: ZRSR2 AND TET2 MUTATIONS PROMOTE MDS BY DYSREGULATING GENE EXPRESSION AND ABERRANT ALTERNATIVE SPLICING IN MICE Garcia-Ruiz, C.; Martínez-Valiente, C.; Liquori, A.; More Garcia-Ruiz, C.; Martínez-Valiente, C.; Liquori, A.; Gutiérrez-Adán, A.; Cervera, J.; Sanjuan-Pla, A. Less HemaSphere. 6:62-63, June 2022. Favorite PDF Permissions Open
S162: SOMATIC GENETIC LANDSCAPE IN GATA2 DEFICIENCY PATIENTS Largeaud, L.; Collin, M.; Monselet, N.; More Largeaud, L.; Collin, M.; Monselet, N.; Vergez, F.; Larcher, L.; Hirsch, P.; Duployez, N.; Bustamante, J.; Bellanné-Chantelot, C.; Donadieu, J.; Sicre de Fontbrune, F.; Nolla, M.; Fieschi, C.; Delhommeau, F.; Delabesse, E.; Pasquet, M. Less HemaSphere. 6:63-64, June 2022. Favorite PDF Permissions Open
S163: EFFICACY OF JAK 1/2 INHIBITION IN MURINE IMMUNE BONE MARROW FAILURE Groarke, E.; Feng, X.; Aggarwal, N.; More Groarke, E.; Feng, X.; Aggarwal, N.; Manley, A. L.; Wu, Z.; Gao, S.; Patel, B.; Chen, J.; Young, N. Less HemaSphere. 6:64-65, June 2022. Favorite PDF Permissions Open
S164: CLONAL DYNAMICS, IMMUNE PHENOTYPES, AND TARGETS OF BONE MARROW-INFILTRATING T CELLS IN ACQUIRED APLASTIC ANEMIA Ben Hamza, A.; Welters, C.; Brüggemann, M.; More Ben Hamza, A.; Welters, C.; Brüggemann, M.; Dietze, K.; Bullinger, L.; Brümmendorf, T. H.; Strobel, J.; Hackstein, H.; Dornmair, K.; Beier, F.; Hansmann, L. Less HemaSphere. 6:65-66, June 2022. Favorite PDF Permissions Open
S165: INTEGRATED GENETIC DIAGNOSTICS OF PATIENTS WITH EARLY ONSET OF DE NOVO MYELODYSPLASTIC SYNDROMES. Attardi, E.; Tiberi, L.; Formicola, D.; More Attardi, E.; Tiberi, L.; Formicola, D.; Artuso, R.; Santini, V. Less HemaSphere. 6:66-67, June 2022. Favorite PDF Permissions Open
S166: MAGROLIMAB IN COMBINATION WITH AZACITIDINE FOR PATIENTS WITH UNTREATED HIGHER-RISK MYELODYSPLASTIC SYNDROMES (HR MDS): 5F9005 PHASE 1B STUDY RESULTS Sallman, D. A.; Al Malki, M. M.; Asch, A. S.; More Sallman, D. A.; Al Malki, M. M.; Asch, A. S.; Wang, E. S.; Jurcic, J. G.; Bradley, T. J.; Flinn, I. W.; Pollyea, D. A.; Kambhampati, S. N.; Tanaka, T. N.; Zeidner, J. F.; Garcia-Manero, G.; Jeyakumar, D.; Gu, L.; Tan, A.; Chao, M.; O’Hear, C.; Lal, I.; Vyas, P.; Daver, N. Less HemaSphere. 6:67-68, June 2022. Favorite PDF Permissions Open
S167: PREDICTION OF RELAPSE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION USING INDIVIDUALIZED MEASURABLE RESIDUAL DISEASE MARKERS; THE PROSPECTIVE NORDIC STUDY NMDSG14B Tobiasson, M.; Pandzic, T.; Illman, J.; More Tobiasson, M.; Pandzic, T.; Illman, J.; Nilsson, L.; Weström, S.; Sollander, K.; Ejerblad, E.; Olsnes Kittang, A.; Olesen, G.; Werlenius, O.; Björklund, A.; Wiggh, J.; lindholm, C.; Lorentz, F.; Rasmussen, B.; Cammenga, J.; Weber, D.; Grönnås, D.; Dimitriou, M.; Kytölä, S.; Walldin, G.; Ljungman, P.; Groenbeck, K.; Mielke, S.; Jacobsen, S. E.; Ebeling, F.; Cavelier, L.; Smidstrup Friis, L.; Dybedal, I.; Hellström-Lindberg, E. Less HemaSphere. 6:68-69, June 2022. Favorite PDF Permissions Open
S168: ERYTHROPOIETIN STIMULATION AGENTS SIGNIFICANTLY IMPROVES OUTCOME IN LOWER RISK MDS. Garelius, H.; Smith, A.; Bagguley, T.; More Garelius, H.; Smith, A.; Bagguley, T.; Taylor, A.; Fenaux, P.; Bowen, D.; Symeonidis, A.; Mittelmann, M.; Stauder, R.; Čermák, J.; Sanz, G.; Langemeijer, S.; Malcovati, L.; Germing, U.; Itzykson, R.; Guerci-Bresler, A.; Culligan, D.; Kotsianidis, I.; Koinig Mag, K.; van Marrewijk, C.; Crouch, S.; de Witte, T.; Hellström-Lindberg, E. Less HemaSphere. 6:69-70, June 2022. Favorite PDF Permissions Open
S169: CLINICAL AND MOLECULAR MARKERS FOR PREDICTING RESPONSE TO ROMIPLOSTIM TREATMENT IN LOWER-RISK MYELODYSPLASTIC SYNDROMES Kubasch, A. S.; Giagounidis, A.; Metzgeroth, G.; More Kubasch, A. S.; Giagounidis, A.; Metzgeroth, G.; Jonasova, A.; Herbst, R.; Diaz, J. M. T.; De Renzis, B.; Götze, K. S.; Huetter-Kroenke, M.-L.; Gourin, M.-P.; Slama, B.; Dimicoli-Salazar, S.; Cony-Makhoul, P.; Laribi, K.; Park, S.; Jersemann, K.; Schipp, D.; Metzeler, K. H.; Tiebel, O.; Sockel, K.; Gloaguen, S.; Mies, A.; Chermat, F.; Thiede, C.; Sapena, R.; Schlenk, R. F.; Fenaux, P.; Platzbecker, U.; Ades, L. Less HemaSphere. 6:70-71, June 2022. Favorite PDF Permissions Open
S170: DYNAMIC INTERPLAY BETWEEN TUMOR AND MICRO-ENVIRONMENT DURING MYELOMA DISEASE PROGRESSION Köse, M. C.; Bergiers, I.; Malfait, M.; More Köse, M. C.; Bergiers, I.; Malfait, M.; Heidrich, B.; De Maeyer, D.; Fourneau, N.; Verbist, B.; Van Houdt, J.; Vanhoof, G.; Verona, R.; Delforge, M.; Depaus, J.; Meuleman, N.; Van Droogenbroeck, J.; Vlummens, P.; Heuck, C. J.; Bahlis, N.; Caers, J.; Casneuf, T. Less HemaSphere. 6:71-72, June 2022. Favorite PDF Permissions Open
S171: MOLECULAR CLUSTERS OF IGM MONOCLONAL GAMMOPATHIES PRESENT DISTINCT BIOLOGIC, IMMUNE AND METABOLIC FEATURES Mondello, P.; Paludo, J.; Novak, J.; More Mondello, P.; Paludo, J.; Novak, J.; Wenzl, K.; Jalali, S.; Krull, J.; Braggio, E.; Dasari, S.; Manske, M; Abeykoon, J.; Vivekananda, S.; Kapoor, P.; Paulus, A.; Reeder, C.; Ailawadhi, S.; Chanan-Khan, A.; Kyle, R.; Gertz, M.; Yang, Z.-Z.; Novak, A.; Ansell, S. Less HemaSphere. 6:72-73, June 2022. Favorite PDF Permissions Open
S172: FUNCTIONAL SUBSETS OF PLASMA CELLS ASSOCIATED WITH AMYLOID PRODUCTION AND Wang, X.; Han, H.; Sun, J.; More Wang, X.; Han, H.; Sun, J.; Wang, Q.; Gao, X.-M.; Shen, K.-N.; Zhang, L.; Zhao, Y.; Cao, X.-X.; Qian, M.; Chen, Y.; Li, J. Less HemaSphere. 6:73-74, June 2022. Favorite PDF Permissions Open
S173: T-CELL ACTIVATION AND MYELOMA CELL KILLING CONFIRM THE MODE OF ACTION OF RG6234, A NOVEL GPRC5D T-CELL ENGAGING BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA Dekhtiarenko, I.; Lelios, I.; Attig, J.; More Dekhtiarenko, I.; Lelios, I.; Attig, J.; Sleiman, N.; Lazzaro, D.; Clausen, I.; Gräfe, N.; Helms, H.-J.; Schindler, E.; Belli, S.; Fauti, T.; Eckmann, J.; Umana, P.; Jacob, W.; Schneider, M.; Hasselbalch Riley, C.; Hutchings, M.; Yoon, S.-S.; Koh, Y; Manier, S.; Facon, T.; Harrison, S. J.; Er, J.; Volzone, F.; Pinto, A.; Montes, C.; Ocio, E. M.; Alfonso-Pierola, A.; Rodríguez Otero, P.; Offner, F.; Guidetti, A.; Corradini, P.; Titouan, C.; Hulin, C.; Touzeau, C.; Moreau, P.; Popat, R.; Leong, S.; Mazza, R.; Carlo-Stella, C.; Bröske, A.-M. E. Less HemaSphere. 6:74-75, June 2022. Favorite PDF Permissions Open
S174: HIGH LEVEL OF CIRCULATING TUMOUR DNA AT DIAGNOSIS CORRELATES WITH DISEASE SPREADING AND DEFINES MULTIPLE MYELOMA PATIENTS WITH POOR PROGNOSIS Martello, M.; Poletti, A.; Bezzi, D.; More Martello, M.; Poletti, A.; Bezzi, D.; Borsi, E.; Taurisano, B.; Solli, V.; Armuzzi, S.; Vigliotta, I.; Mazzocchetti, G.; Pistis, I.; Pantani, L.; Rocchi, S.; Mancuso, K.; Tacchetti, P.; Rizzello, I.; Cavo, M.; Zamagni, E.; Nanni, C.; Terragna, C. Less HemaSphere. 6:75-76, June 2022. Favorite PDF Permissions Open
S175: ATLAS: A PHASE 3 RANDOMIZED TRIAL OF CARFILZOMIB, LENALIDOMIDE, AND DEXAMETHASONE VERSUS LENALIDOMIDE ALONE AFTER STEM-CELL TRANSPLANT FOR MULTIPLE MYELOMA Dytfeld, D.; Wróbel, T.; Jamroziak, K.; More Dytfeld, D.; Wróbel, T.; Jamroziak, K.; Kubicki, T.; Robak, P.; Walter-Croneck, A.; Czyż, J.; Tyczyńska, A.; Druzd-Sitek, A.; Giannopoulos, K.; Nowicki, A.; Szczepaniak, T.; Łojko-Dankowska, A.; Matuszak, M.; Gil, L.; Puła, B.; Rybka, J.; Majcherek, M.; Usnarska-Zubkiewicz, L.; Szukalski, L.; Końska, A.; Zaucha, J. M.; Walewski, J.; Mikulski, D.; Czabak, O.; Robak, T.; Grzybowska, U.; Lahoud, O. B.; Zonder, J. A.; Griffith, K.; Stefka, A.; Major, A.; Derman, B. A.; Jakubowiak, A. J. Less HemaSphere. 6:76-77, June 2022. Favorite PDF Permissions Open
S176: DARATUMUMAB CARFILZOMIB LENALIDOMIDE AND DEXAMETHASONE AS INDUCTION THERAPY IN HIGH-RISK TRANSPLANT ELIGIBLE NEWLY DIAGNOSED MYELOMA PATIENTS: RESULTS OF THE PHASE 2 STUDY IFM 2018-04 Touzeau, C.; Perrrot, A.; Hulin, C.; More Touzeau, C.; Perrrot, A.; Hulin, C.; Manier, S.; Macro, M.; Chretien, M.-L.; Karlin, L.; Decaux, O.; Jacquet, C.; Tiab, M.; Leleu, X.; Planchce, L.; Avet-Loiseau, H.; Moreau, P. Less HemaSphere. 6:77-78, June 2022. Favorite PDF Permissions Open
S177: EVALUATING SERUM FREE LIGHT CHAIN RATIO AS A BIOMARKER FOR MULTIPLE MYELOMA Akhlaghi, T.; Maclachlan, K.; Korde, N.; More Akhlaghi, T.; Maclachlan, K.; Korde, N.; Mailankody, S.; Lesokhin, A.; Hassoun, H.; Lu, S. X.; Patel, D.; Shah, U.; Tan, C.; Derkach, A.; Lahoud, O.; Landau, H. J.; Shah, G. L.; Scordo, M.; Chung, D. J.; Giralt, S. A.; Usmani, S. Z.; Landgren, O.; Hultcrantz, M. Less HemaSphere. 6:78-79, June 2022. Favorite PDF Permissions Open
S178: SAFETY AND EFFICACY OF BELANTAMAB MAFODOTIN IN COMBINATION WITH RD IN NEWLY DIAGNOSED, TRANSPLANT INELIGIBLE MULTIPLE MYELOMA PATIENTS: A PHASE 1/2 STUDY BY THE HELLENIC SOCIETY OF HEMATOLOGY Terpos, E.; Gavriatopoulou, M.; Ntanasis-Stathopoulos, I.; More Terpos, E.; Gavriatopoulou, M.; Ntanasis-Stathopoulos, I.; Malandrakis, P.; Fotiou, D.; Kanellias, N.; Gkolfinopoulos, S.; Manousou, K.; Kastritis, E.; Dimopoulos, M.-A. Less HemaSphere. 6:79-80, June 2022. Favorite PDF Permissions Open
S179: RANDOMIZED COMPARISON BETWEEN KRD AND KTD INDUCTION, FOLLOWED BY K MAINTENANCE OR OBSERVATION IN TRANSPLANT NON-ELIGIBLE PATIENTS WITH NDMM (AGMT-MM02 TRIAL) Ludwig, H.; Melchardt, T.; Sormann, S.; More Ludwig, H.; Melchardt, T.; Sormann, S.; Zojer, N.; Andel, J.; Hartmann, B.; Tinchon, C.; Gunsilius, E.; Podar, K.; Egle, A.; Willenbacher, W.; Wöll, E.; Schreder, M.; Ruckser, R.; Bozic, B; Krauth, M.-T.; Petzer, A.; Schmitt, C; Machherndl-Spandl, S.; Agis, H.; Fillitz, M.; Pönisch, W.; Knop, S.; Paiva, B.; Greil, R. Less HemaSphere. 6:80-81, June 2022. Favorite PDF Permissions Open
S180: RG6234, A NOVEL GPRC5D T-CELL ENGAGING BISPECIFIC ANTIBODY, INDUCES RAPID RESPONSES IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: PRELIMINARY RESULTS FROM A FIRST-IN-HUMAN TRIAL Hasselbalch Riley, C.; Hutchings, M.; Yoon, S.-S.; More Hasselbalch Riley, C.; Hutchings, M.; Yoon, S.-S.; Koh, Y.; Manier, S.; Facon, T.; Harrison, S. J.; Er, J.; Volzone, F.; Pinto, A.; Montes, C.; Ocio, E. M.; Alfonso-Pierola, A.; Rodriguez Otero, P.; Offner, F.; Guidetti, A.; Corradini, P.; Titouan, C.; Hulin, C.; Touzeau, C.; Moreau, P.; Popat, R.; Leong, S.; Mazza, R.; Bröske, A.-M. E.; Dekhtiarenko, I.; Helms, H.-J.; Belli, S.; Vardar, T.; Fauti, T.; Eckmann, J.; Moore, T.; Schneider, M.; Jacob, W.; Weisser, M.; Carlo-Stella, C. Less HemaSphere. 6:81-82, June 2022. Favorite PDF Permissions Open
S181: MODAKAFUSP ALFA (TAK-573): UPDATED CLINICAL, PHARMACOKINETIC (PK), AND IMMUNOGENICITY RESULTS FROM A PHASE 1/2 STUDY IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) Kaufman, J. L.; Atrash, S.; Holstein, , S. A.; More Kaufman, J. L.; Atrash, S.; Holstein, , S. A.; Nadeem, O.; Benson, D; Suryanarayan, K.; Liu, Y.; Li, C.; Yang, L.; Parot, X.; Vogl, D. T. Less HemaSphere. 6:82-83, June 2022. Favorite PDF Permissions Open
S182: TALQUETAMAB, A G PROTEIN-COUPLED RECEPTOR FAMILY C GROUP 5 MEMBER D X CD3 BISPECIFIC ANTIBODY, IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: UPDATED EFFICACY AND SAFETY RESULTS FROM MONUMENTAL-1 Minnema, M. C.; Krishnan, A.; Berdeja, J. G.; More Minnema, M. C.; Krishnan, A.; Berdeja, J. G.; Oriol, A.; van de Donk, N. W.; Rodríguez-Otero, P.; Morillo, D.; Mateos, M.-V.; Costa, L. J.; Caers, J.; Vishwamitra, D.; Ma, J.; Yang, S.; Hilder, B. W.; Tolbert, J.; Goldberg, J. D.; Chari, A. Less HemaSphere. 6:83-84, June 2022. Favorite PDF Permissions Open
S183: NOVEL COMBINATION IMMUNOTHERAPY FOR THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA: UPDATED PHASE 1B RESULTS FOR TALQUETAMAB (A GPRC5D X CD3 BISPECIFIC ANTIBODY) IN COMBINATION WITH DARATUMUMAB van de Donk, N. W.; Bahlis, N.; Mateos, M.-V.; More van de Donk, N. W.; Bahlis, N.; Mateos, M.-V.; Weisel, K.; Dholaria, B.; Garfall, A. L.; Goldschmidt, H.; Martin, T. G.; Morillo, D.; Reece, D. E.; Hurd, D.; Rodríguez-Otero, P.; Bhutani, M.; D’Souza, A.; Oriol, A.; Askari, E.; San-Miguel, J. F.; Kortüm, K. M.; Vishwamitra, D.; Xin Wang Lin, S.; Prior, T. J.; Vandenberk, L.; Smit, M.-A. D.; Goldberg, J. D.; Wäsch, R.; Chari, A. Less HemaSphere. 6:84-85, June 2022. Favorite PDF Permissions Open
S184: EVALUATING TECLISTAMAB IN PATIENTS WITH RELAPSED/ REFRACTORY MULTIPLE MYELOMA FOLLOWING EXPOSURE TO OTHER B-CELL MATURATION ANTIGEN (BCMA)-TARGETED AGENTS Touzeau, C.; Krishnan, A.; Moreau, P.; More Touzeau, C.; Krishnan, A.; Moreau, P.; Perrot, A.; Usmani, S. Z.; Manier, S.; Cavo, M.; Martinez-Chamorro, C.; Nooka, A.; Martin, T.; Karlin, L.; Leleu, X.; Bahlis, N.; Besemer, B.; Pei, L.; Verona, R.; Girgis, S.; Uhlar, C.; Kobos, R.; Garfall, A. Less HemaSphere. 6:85-86, June 2022. Favorite PDF Permissions Open
S185: CARTITUDE-2 COHORT B: UPDATED CLINICAL DATA AND BIOLOGICAL CORRELATIVE ANALYSES OF CILTACABTAGENE AUTOLEUCEL IN PATIENTS WITH MULTIPLE MYELOMA AND EARLY RELAPSE AFTER INITIAL THERAPY Agha, M. E.; van de Donk, N. W.; Cohen, A. D.; More Agha, M. E.; van de Donk, N. W.; Cohen, A. D.; Cohen, Y. C.; Anguille, S.; Kerre, T.; Roeloffzen, W.; Schecter, J. M.; De Braganca, K. C.; Varsos, H.; Mistry, P.; Roccia, T.; Zudaire, E.; Corsale, C.; Akram, M.; Geng, D.; Nesheiwat, T; Pacaud, L.; Sonneveld, P.; Zweegman, S. Less HemaSphere. 6:86-87, June 2022. Favorite PDF Permissions Open
S186: UPDATED RESULTS OF A MULTICENTER FIRST-IN-HUMAN STUDY OF BCMA/CD19 DUAL-TARGETING FAST CAR-T GC012F FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) Du, J.; Jiang, H.; Dong, B.; More Du, J.; Jiang, H.; Dong, B.; Gao, L.; Liu, L.; Ge, J.; He, A.; Li, L.; Lu, J.; Chen, X.; Sersch, M.; Zhang, H.; Shen, L.; Liu, J.; Fu, W. Less HemaSphere. 6:87-88, June 2022. Favorite PDF Permissions Open
S187: UPDATED PHASE 1/2 DATA OF SAFETY AND EFFICACY OF CT103A, FULLY HUMAN BCMA-DIRECTED CAR T CELLS, IN RELAPSED/REFRACTORY MULTIPLE MYELOMA Li, C.; Wang, D.; Song, Y.; More Li, C.; Wang, D.; Song, Y.; Li, J.; Huang, H; Chen, B.; Liu, J.; Hu, K.; Ren, H.; Zhang, X.; Li, Z.; Zou, D.; Yin, Q.; Chen, L.; Hu, Y.; Xu, Y.; Cheng, Q.; Guo, Y.; Dong, Y.; Gao, L.; Chen, S.; Xu, A.; Cai, S.; Wu, M.; Guo, J.; Yao, Z.; Wang, W.; Wang, J.; Chen, L.; Zhou, J.; Qiu, L. Less HemaSphere. 6:88-89, June 2022. Favorite PDF Permissions Open
S188: TECLISTAMAB IN COMBINATION WITH DARATUMUMAB, A NOVEL, IMMUNOTHERAPY-BASED APPROACH FOR THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA: UPDATED PHASE 1B RESULTS Rodriguez Otero, P.; D’Souza, A.; Reece, D.; More Rodriguez Otero, P.; D’Souza, A.; Reece, D.; van de Donk, N. W.; Chari, A.; Krishnan, A.; Martin, T.; Mateos, M. V.; Morillo, D.; Hurd, D.; Rosinol, L.; Balari, A. S.; Wäsch, R.; Vishwamitra, D.; Wang Lin, S. X.; Prior, T.; Vandenberk, L.; Smit, M.-A. D.; Oriol, A.; Dholaria, B. Less HemaSphere. 6:89-90, June 2022. Favorite PDF Permissions Open
S189: EARLY, DEEP, AND DURABLE RESPONSES, AND LOW RATES OF CRS WITH REGN5458, A BCMAXCD3 BISPECIFIC ANTIBODY, IN A PHASE 1/2 FIRST-IN-HUMAN STUDY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA Zonder, J. A.; Richter, J.; Bumma, N.; More Zonder, J. A.; Richter, J.; Bumma, N.; Brayer, J.; Hoffman, J. E.; Bensinger, W. I.; Wu, K. L.; Xu, L.; Chokshi, D.; Boyapati, A.; Cronier, D.; Houvras, Y.; Rodriguez Lorenc, K.; Kroog, G. S.; Dhodapkar, M. V.; Lentzsch, S.; Cooper, D.; Jagannath, S. Less HemaSphere. 6:90-91, June 2022. Favorite PDF Permissions Open
S190: ASXL1 MUTATIONS ACCELERATE BONE MARROW FIBROSIS VIA EGR1-TNFA AXIS MEDIATED INFLAMMATION AND FIBROCYTE GENERATION IN MYELOPROLIFERATIVE NEOPLASMS Shi, Z.; Liu, J.; Zhao, Y.; More Shi, Z.; Liu, J.; Zhao, Y.; Yang, L.; Cai, Y.; Zhang, P.; Xu, Z.; Qin, T.; Qu, S.; Pan, L.; Wu, J.; Yan, X.; Li, Z.; Zhang, W.; Yan, Y.; Huang, H.; Huang, G.; Li, B.; Wu, X.; Xiao, Z. Less HemaSphere. 6:91-92, June 2022. Favorite PDF Permissions Open
S191: CALRETICULIN-MUTATED HEMATOPOIETIC CELLS ARE VULNERABLE TO THE COMBINED INHIBITION OF THE PROTEASOME AND THE IRE1A-XBP1 AXIS OF THE UNFOLDED PROTEIN RESPONSE Jutzi, J. S.; Marneth, A. E.; Jimenez-Santos, M. J.; More Jutzi, J. S.; Marneth, A. E.; Jimenez-Santos, M. J.; Guerra-Moreno, A.; Myers, S. A.; Carr, S. A.; van Galen, P.; Al-Shahrour, F.; Nam, A. S.; Mullally, A. Less HemaSphere. 6:92-93, June 2022. Favorite PDF Permissions Open
S192: SINGLE-CELL RNA PROFILING OF MYELOFIBROSIS PATIENTS REVEALS PELABRESIB-INDUCED DECREASE OF MEGAKARYOCYTIC PROGENITORS AND NORMALIZATION OF CD4+ T CELLS IN PERIPHERAL BLOOD Zavidij, O.; Haradhvala, N. J.; Meyer, R.; More Zavidij, O.; Haradhvala, N. J.; Meyer, R.; Cui, J.; Verstovsek, S.; Oh, S.; Mead, A.; Taverna, P. Less HemaSphere. 6:93-94, June 2022. Favorite PDF Permissions Open
S193: GENOMIC AND FUNCTIONAL IMPACT OF TP53 INACTIVATION IN JAK2V617F MYELOPROLIFERATIVE NEOPLASMS: A TRANSGENIC MOUSE MODEL APPROACH. GOU, P.; LIU, D.; Lauret, E.; More GOU, P.; LIU, D.; Lauret, E.; Maslah, N.; Montcuquet, V.; meignin, V.; Kiladjian, J.-J.; Cassinat, B.; Giraudier, S. Less HemaSphere. 6:94-95, June 2022. Favorite PDF Permissions Open
S194: INTEGRATIVE CLINICAL PROTEOTYPING AND DRUG RESPONSE PROFILING IDENTIFIES TARGETABLE BIOLOGY UNDERLYING MYELOPROLIFERATIVE NEOPLASMS Wildschut, M. H.; van Oostrum, M.; Settelmeier, J.; More Wildschut, M. H.; van Oostrum, M.; Settelmeier, J.; Mena, J.; Dördelmann, C.; Festl, Y.; Ring, A.; Skoda, R. C.; Lopes, M.; Wollscheid, B.; Snijder, B.; Theocharides, A. Less HemaSphere. 6:95-96, June 2022. Favorite PDF Permissions Open
S195: MOMENTUM: PHASE 3 RANDOMIZED STUDY OF MOMELOTINIB (MMB) VERSUS DANAZOL (DAN) IN SYMPTOMATIC AND ANEMIC MYELOFIBROSIS (MF) PATIENTS PREVIOUSLY TREATED WITH A JAK INHIBITOR Verstovsek, S.; Vannucchi, A.; Gerds, A.; More Verstovsek, S.; Vannucchi, A.; Gerds, A.; Al-Ali, H. K.; Lavie, D.; Kuykendall, A.; Grosicki, S.; Iurlo, A.; Goh, Y. T.; Lazaroiu, M.; Egyed, M.; Fox, M. L.; McLornan, D.; Perkins, A.; Yoon, S.-S.; Gupta, V.; Kiladjian, J.-J.; Donahue, R.; Kawashima, J.; Mesa, R. Less HemaSphere. 6:96-97, June 2022. Favorite PDF Permissions Open
S196: ROPEGINTERFERON ALFA-2B ACHIEVES PATIENT-SPECIFIC TREATMENT GOALS IN POLYCYTHEMIA VERA: FINAL RESULTS FROM THE PROUD-PV/CONTINUATION-PV STUDIES Gisslinger, H.; Klade, C.; Georgiev, P.; More Gisslinger, H.; Klade, C.; Georgiev, P.; Krochmalczyk, D.; Gercheva-Kyuchukova, L.; Egyed, M.; Dulicek, P.; Illes, A.; Pylypenko, H.; Sivcheva, L.; Mayer, J.; Yablokova, V.; Empson, V.; Krejcy, K.; Hasselbalch, H.; Kralovics, R.; Kiladjian, J.-J. Less HemaSphere. 6:97-98, June 2022. Favorite PDF Permissions Open
S197: NAVITOCLAX PLUS RUXOLITINIB IN JAK INHIBITOR-NAÏVE PATIENTS WITH MYELOFIBROSIS: PRELIMINARY SAFETY AND EFFICACY IN A MULTICENTER, OPEN-LABEL PHASE 2 STUDY Passamonti, F.; Foran, J.; Tandra, A.; More Passamonti, F.; Foran, J.; Tandra, A.; De Stefano, V.; Laura Fox, M.; Mattour, A.; McMullin, M. F.; Perkins, A. C.; Rodriguez-Macías, G.; Sibai, H.; Qin, Q.; Potluri, J.; How, J. Less HemaSphere. 6:98-99, June 2022. Favorite PDF Permissions Open
S198: BET INHIBITOR PELABRESIB (CPI-0610) COMBINED WITH RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS — JAK INHIBITOR-NAÏVE OR WITH SUBOPTIMAL RESPONSE TO RUXOLITINIB — PRELIMINARY DATA FROM THE MANIFEST STUDY Mascarenhas, J.; Kremyanskaya, M.; Patriarca, A.; More Mascarenhas, J.; Kremyanskaya, M.; Patriarca, A.; Harrison, C.; Bose, P.; Rampal, R. K.; Palandri, F; Devos, T.; Passamonti, F.; Hobbs, G.; Talpaz, M.; Vannucchi, A.; Kiladjian, J.-J.; Verstovsek, S.; Hoffman, R.; Salama, M. E.; Chen, D.; Taverna, P.; Chang, A.; Colak, G.; Klein, S.; Gupta, V. Less HemaSphere. 6:99-100, June 2022. Favorite PDF Permissions Open
